Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties

Lastest posts

View all posts->
December
04
-
,
2025
- release at
CET
US

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement

NEW YORK, NY, and SOUTH SAN FRANCISCO, CA, DECEMBER 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa.
November
04
-
,
2025
- release at
CET
US

Royalty Pharma Acquires Royalty Interest in Alnylam’s Amvuttra for $310 Million from Blackstone Life Sciences

Royalty Pharma Acquires Royalty Interest in Alnylam’s Amvuttra for $310 Million from Blackstone Life Sciences

NEW YORK, NY, and CAMBRIDGE, MA NOVEMBER 4, 2025 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam, in which Blackstone invested to support AMVUTTRA’s pivotal Phase 3 HELIOS-B trial.
September
01
-
,
2025
- release at
CET

Tokenization in Biopharma Licensing

Tokenization in Biopharma Licensing

How Tokenization can Transform Pharma Licensing and Royalty Financing The pharmaceutical and biotech industries face a critical financing paradox: groundbreaking medical innovations require massive capital investment, yet traditional funding mechanisms create significant barriers to accessing the capital needed to bring life-saving treatments to market.
View all posts->

Get your free royalty value estimate

Use our interactive tool to get your value estimation now. Simply enter your key details and see the calculation.

Start Calculation